Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Research & Development (2017 - 2019)

Historic Research & Development for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to $583778.0.

  • Monopar Therapeutics' Research & Development rose 1205.34% to $583778.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $2.0 million, marking a year-over-year increase of 2415.83%. This contributed to the annual value of $2.0 million for FY2019, which is 1093.65% up from last year.
  • As of Q4 2019, Monopar Therapeutics' Research & Development stood at $583778.0, which was up 1205.34% from $219846.0 recorded in Q3 2019.
  • Monopar Therapeutics' 5-year Research & Development high stood at $835600.0 for Q1 2019, and its period low was $133736.0 during Q1 2017.
  • For the 3-year period, Monopar Therapeutics' Research & Development averaged around $374110.7, with its median value being $310454.0 (2017).
  • In the last 5 years, Monopar Therapeutics' Research & Development surged by 24182.34% in 2018 and then tumbled by 2760.7% in 2019.
  • Monopar Therapeutics' Research & Development (Quarter) stood at $309315.0 in 2017, then surged by 68.43% to $520982.0 in 2018, then increased by 12.05% to $583778.0 in 2019.
  • Its Research & Development was $583778.0 in Q4 2019, compared to $219846.0 in Q3 2019 and $329294.0 in Q2 2019.